



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/438,030	11/10/1999	Mir A Imran	PERCUS.093A	8801
20995 75	590 06/14/2002			
KNOBBE MARTENS OLSON & BEAR LLP 620 NEWPORT CENTER DRIVE SIXTEENTH FLOOR			EXAMINER	
			SERKE, CATHERINE	
NEWPORT BEACH, CA 92660			ART UNIT	PAPER NUMBER
			3763	11
			DATE MAILED: 06/14/2002	2

Please find below and/or attached an Office communication concerning this application or proceeding.

	<u> </u>	Application No.	Applicant(s)			
Office Action Summary						
		09/438,030	IMRAN ET AL.			
		Examiner Serke	Art Unit			
	The MAILING DATE of this communication app	Catherine Serke ears on the cover sheet wi	th the correspondence address			
Period for Reply						
THE I - Exter after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nations of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a rewithin the statutory minimum of thirt ill apply and will expire SIX (6) MON cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. & 133)			
1)⊠	Responsive to communication(s) filed on 18 M	<u>1arch 2002</u> .				
2a)⊠	This action is FINAL. 2b) ☐ Thi	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
• —	on of Claims					
• -	Claim(s) <u>1-46</u> is/are pending in the application					
_	4a) Of the above claim(s) is/are withdrawn from consideration. Claim(s) <u>1-39</u> is/are allowed.					
·	6)⊠ Claim(s) <u>40-42</u> is/are rejected.					
	(i)					
	Claim(s) are subject to restriction and/or	election requirement				
	on Papers	oloollon requirement.				
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the		• •			
11) 🔲 .	The proposed drawing correction filed on	is: a)□ approved b)□ d	isapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)[a) ☐ All b) ☐ Some * c) ☐ None of:					
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>10</u>	5) Notice of I	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152)			

DETAILED ACTION

Claim Objections

Claim 3 is objected to because of the following informalities: the first line of the claim incorrectly spells "from" as form. Appropriate correction is required.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 40-41 are rejected under 35 U.S.C. 102(e) as being anticipated by Frisbie.

Frisbie discloses a method for the treatment of an occlusion in a blood vessel which includes the steps of (1) prior to performing treatment on the occlusion crossing the occlusion with a guidewire and an aspiration catheter in a proximal to distal direction while aspirating blood. See column 5 lines 42-56. The prior art also teaches positioning a distal end of a guidewire proximal to at least a portion of an occlusion (5:5-13), introducing an aspiration

Application/Control Number: 09/438,030 Page 3

Art Unit: 3763

to secolite for the first

the site of the occlusion with both the distal end of the guidewire and a distal end of the aspiration catheter (5:60-63), and evacuating the occlusion (6:7-11). It is considered inherent that after the guidewire has been moved across the occluded region that either at some point during the procedure or during the removal of the device the distal end of the aspiration catheter will be moved in a distal to proximal direction.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 42 is rejected under 35 U.S.C. 103(a) as being unpatentable over Frisbie.

With regard to claim 42, Frisbie meets the claim limitations as described above but fails to specifically teach further aspirating while moving the distal end of the aspiration catheter in a distal to proximal direction.

At the time of the invention it would have been obvious to aspirate during the totality of the procedure since the disclosure of Frisbie points to the importance of removing all of the loose fragments that may have been dislodged from the vessel wall. Continuing aspiration during removal of the device would enhance the ability to withdraw any fragments that were missed during the procedure.

Application/Control Number: 09/438,030

Art Unit: 3763

Response to Arguments

Applicant's arguments filed 3/18/02 have been fully considered but they are not persuasive. Regarding new claims 40-42, applicant has failed to distinguish the new claim from the prior art of record. Frisbie locates the guidewire first proximal to the occlusion and then distal to the occlusion after crossing the site with the aspiration catheter.

Allowable Subject Matter

Claims 1-39 are allowed.

Claims 43-46 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Application/Control Number: 09/438,030

Art Unit: 3763

Page 5

however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine Serke whose telephone number is 703-308-4846. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 703-308-3552. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9302 for regular communications and 703-872-9303 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-2192.

Catherine Serke (b. . June 10, 2002

BRIAN L. CASLER SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700